Methods of producing erythropoietin isoforms comprising...

Details Methods of producing erythropoietin isoforms comprising... Methods of producing erythropoietin isoforms comprising...

2007-06-20

2010-11-16

Carlson, Karen Cochrane (Department: 1652)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069600, C435S070300, C514S012200, C514S061000, C530S324000, C530S380000

Reexamination Certificate

active

07833753

ABSTRACT:
Disclosed are immortalized human embryonic retina cells, having a nucleic acid sequence encoding an adenoviral E1A protein integrated into the genome of the cells, and further comprising a nucleic acid sequence encoding an enzyme involved in post-translational modification of proteins, such as a sialyltransferase, wherein the nucleic acid sequence encoding the enzyme involved in post-translational modification of proteins is under control of a heterologous promoter. Methods for producing recombinant proteins from such cells and obtaining such recombinant proteins having increased sialylation are provided as are novel compositions of isoforms of erythropoietin.

REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4835260 (1989-05-01), Shoemaker
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5192539 (1993-03-01), Van Der Marel et al.
patent: 5441868 (1995-08-01), Lin
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5494790 (1996-02-01), Sasaki et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5631158 (1997-05-01), Dorai et al.
patent: 5714587 (1998-02-01), Laine
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5789247 (1998-08-01), Ballay et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5835382 (1998-11-01), Wilson et al.
patent: 5856292 (1999-01-01), Thomas et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6395519 (2002-05-01), Fallaux et al.
patent: 6413746 (2002-07-01), Field
patent: 6475753 (2002-11-01), Ruben et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6506598 (2003-01-01), Andersen et al.
patent: 6558948 (2003-05-01), Kochanek et al.
patent: 6653101 (2003-11-01), Cockett et al.
patent: 6855544 (2005-02-01), Hateboer et al.
patent: 6878549 (2005-04-01), Vogels et al.
patent: 7125706 (2006-10-01), Zhang et al.
patent: 7132280 (2006-11-01), Bout et al.
patent: 7163787 (2007-01-01), Brus et al.
patent: 7192759 (2007-03-01), Pau et al.
patent: 7297680 (2007-11-01), Opstelten et al.
patent: 7304031 (2007-12-01), Opstelten et al.
patent: 7335490 (2008-02-01), Van Gilst et al.
patent: 7425437 (2008-09-01), UytdeHaag et al.
patent: 7470523 (2008-12-01), Bout et al.
patent: 7491532 (2009-02-01), Bout et al.
patent: 7504248 (2009-03-01), Marzio et al.
patent: 7521220 (2009-04-01), Pau et al.
patent: 7527961 (2009-05-01), Pau et al.
patent: 7550284 (2009-06-01), Pau et al.
patent: 7604960 (2009-10-01), Hateboer et al.
patent: 7608431 (2009-10-01), Yallop
patent: 7642078 (2010-01-01), Opstelten
patent: 2002/0116723 (2002-08-01), Grigliatti et al.
patent: 2002/0182723 (2002-12-01), Zhang et al.
patent: 2003/0087437 (2003-05-01), Asada et al.
patent: 2003/0092160 (2003-05-01), Bout et al.
patent: 2005/0106722 (2005-05-01), Jones et al.
patent: 2005/0164386 (2005-07-01), Uytdehaag et al.
patent: 2005/0170398 (2005-08-01), Van Berkel et al.
patent: 2005/0170463 (2005-08-01), Bout et al.
patent: 2005/0181359 (2005-08-01), Optelten et al.
patent: 2006/0121611 (2006-06-01), Yallop
patent: 2007/0117742 (2007-05-01), Opstelten et al.
patent: 2007/0231860 (2007-10-01), UytdeHaag et al.
patent: 2008/0032922 (2008-02-01), Opstelten et al.
patent: 2008/0050403 (2008-02-01), Marzio et al.
patent: 2009/0017068 (2009-01-01), UytdeHaag et al.
patent: 2009/0170164 (2009-07-01), Bout
patent: 2009/0239287 (2009-09-01), Pau et al.
patent: 2009/0324645 (2009-12-01), Pau et al.
patent: 0 185 573 (1986-06-01), None
patent: 0 411 678 (1991-02-01), None
patent: 0 833 934 (1998-04-01), None
patent: 1 108 787 (2001-06-01), None
patent: WO 93/03163 (1993-02-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 95/29994 (1995-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 97/18318 (1997-05-01), None
patent: WO 98/18926 (1998-05-01), None
patent: WO 98/39411 (1998-09-01), None
patent: WO 98/44141 (1998-10-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/24068 (1999-05-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/05945 (2001-01-01), None
patent: WO 01/38362 (2001-05-01), None
patent: WO 0188117 (2001-11-01), None
patent: WO 02/18948 (2002-03-01), None
patent: WO 02/053580 (2002-07-01), None
patent: WO 03/038100 (2003-05-01), None
patent: WO 03/048197 (2003-06-01), None
patent: WO 03/048348 (2003-06-01), None
patent: WO 03/051927 (2003-06-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/058944 (2004-07-01), None
patent: WO 2004/099396 (2004-11-01), None
patent: WO 2004/099396 (2004-11-01), None
Bout et al., “Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors,” Cancer Gene Therapy, 1996, pp. S24, vol. 3, No. 6.
Bout et al., “Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6,” Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.
Boutl et al., A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, vol. 4, No. 6.
European Search Report 05 10 0732, Apr. 7, 2005.
Fallaux et al, “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Human Gene Therapy, Sep. 1, 1998, vol. 9, No. 1, pp. 1909-1917. Abstract.
Ghosh-Choudhury et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-1739, vol. 6, No. 6.
Grand et al., “Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells,” Eur Mol Biol Organ J. 1986, 5 (6) 1253-1260. Abstract.
Grand et al., “The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression,” Virology, 1995, vol. 210, No. 2, pp. 323-334. Abstract.
Louis et al., Cloning and Sequencing of the Cellular—Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-429, vol. 233.
Setoguchi et al., “Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector,” Blood, Nov. 1, 1994, pp. 2946-2953, vol. 84, No. 9.
Yu et al., “Enhanced c-erbB-2
eu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A,” Cancer Res., 1993, 53 (4) 891-8. Abstract.
Grabenhorst et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GIcNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1-4)G1cNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 718-725, vol. 232, No. 3, Berlin, Germany.
Hollister et al., Stable expression of mammalian beta1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells, Glycobiology, 1998, pp. 473-480, vol. 8, No. 5, IRL Press, United Kingdom.
Jenkins et al., Getting the glycosylation right: Implications for the biotechnology industry, Nature Biotechnology, Aug. 1996, pp. 975-981, vol. 14, No. 8, Nature Publishing, US.
Minch et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialyltransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)Glc-N-AcR Linkages, Biotechnol. Prog., 1995, pp. 348-351, vol. 11, No. 3.
Pacitti et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-1415, vol. 61, No. 5, American Society for Microbiology.
Schiedner et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenovi

Affiliated with

Also associated with

Rating

Methods of producing erythropoietin isoforms comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of producing erythropoietin isoforms comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of producing erythropoietin isoforms comprising... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4182553